Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Large Decrease in Short Interest

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 795,900 shares, a drop of 20.4% from the March 15th total of 1,000,000 shares. Based on an average daily trading volume, of 268,400 shares, the short-interest ratio is presently 3.0 days. Approximately 2.6% of the company's stock are sold short.

Repare Therapeutics Stock Down 6.6 %

Shares of NASDAQ:RPTX traded down $0.09 on Wednesday, reaching $1.28. The company had a trading volume of 724,199 shares, compared to its average volume of 273,334. The stock has a market capitalization of $54.41 million, a P/E ratio of -0.64 and a beta of 0.91. The stock has a 50-day moving average price of $1.12 and a 200 day moving average price of $1.93. Repare Therapeutics has a twelve month low of $0.89 and a twelve month high of $4.29.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.77) by $0.10. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 40.87%. On average, sell-side analysts predict that Repare Therapeutics will post -2.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on RPTX shares. HC Wainwright decreased their price objective on Repare Therapeutics from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Friday, March 7th. Bloom Burton downgraded Repare Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, January 10th.

Institutional Investors Weigh In On Repare Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Stifel Financial Corp increased its position in shares of Repare Therapeutics by 36.4% during the third quarter. Stifel Financial Corp now owns 51,700 shares of the company's stock valued at $178,000 after purchasing an additional 13,800 shares during the period. Barclays PLC increased its holdings in Repare Therapeutics by 1,471.7% in the 3rd quarter. Barclays PLC now owns 8,330 shares of the company's stock valued at $29,000 after buying an additional 7,800 shares during the period. Vontobel Holding Ltd. increased its holdings in Repare Therapeutics by 45.8% in the 4th quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company's stock valued at $46,000 after buying an additional 11,000 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Repare Therapeutics by 2,144,950.0% in the 4th quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company's stock valued at $112,000 after buying an additional 85,798 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Repare Therapeutics by 204.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company's stock worth $45,000 after acquiring an additional 23,127 shares during the period. 85.09% of the stock is owned by institutional investors and hedge funds.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.